CB-5083 is a potent, selective, and orally bioavailable p97 AAA ATPase inhibitor ( IC50=11 nM).

Eeyarestatin I is an inhibitor that inhibits the degradation and translocation of ER-associated proteins. Eeyarestatin I is associated with the p97 deubiquitination process and inhibits atx3 deubiquitination. Eeyarestatin I has anticancer effects by inducing proteins that cause cell death.

p97-IN-1 is a potent inhibitor of p97 with an IC 50 <30 nM [1].

NMS-859 is an effective and covalent inhibitor of valosin-containing protein (VCP)/p97 with IC50s of 0.37 μM and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.

NMS-873 is a potent and selective allosteric inhibitor of VCP/p97.

DBEQ (JRF 12) is a selective, potent, reversible, and ATP-competitive p97 inhibitor.

ML240 is a selective, ATP-competitive p97 inhibitor.

NPD8733 is an inhibitor of cancer cell-enhanced fibroblast migration, specifically binding to valosin-containing protein (VCP)/p97.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

ML241 is a potent and selective inhibitors of p97 ATPase.ML241 inhibits degradation of a p97-dependent but not a p97-independent proteasome substrate in a dual-reporter cell line. ML241 may be a novel agent for the chemotherapy of cancer, and provide a rationale for developing pathway-specific p97 inhibitors.

MSC1094308 is a reversible, non-ATP-competitive alterative inhibitor targeting type II AAA ATPase (VCP/p97) and type I AAA ATPase (VPS4B), which affects the intracellular protein degradation process by binding to a specific hotspot region of p97 and inhibiting D2 ATPase activity.

UPCDC30245 is an AAA ATPase p97 allosteric inhibitor.

UP163 enhances ATPase activity and activates valosin-containing protein (VCP), with an EC50 of 9.0 μM. It also reduces MG-132-induced TDP-43 aggregation.

UP158 enhances ATPase activity and stimulates valosin-containing protein (VCP), with an EC50 of 2.57 μM.

NSC799462, a triazole inhibitor, specifically targets p97 ATPase, exerting its effect by binding to a designated site on the p97 enzyme. This interaction induces localized structural alterations in p97, effectively inhibiting its ATPase activity with an IC 50 value of 15 nM.

NSC819701 is a triazole-based inhibitor of p97ATPase. It inhibits the activity of p97ATPase by binding to specific sites on p97.

VCP/p97 IN-3 is an allosteric inhibitor of VCP/p97. It exhibits inhibitory activity against VCP, with an IC50 of 9 nM, and shows IC50 values of 12 nM (N660K) and 19 nM (V474A/D649A) for mutant VCP proteins. VCP/p97 IN-3 increases the levels of K48 ubiquitination and caspase-3. It activates endoplasmic reticulum stress and the unfolded protein response (UPR). In a subcutaneous xenograft mouse model with RPMI-8226 cells, VCP/p97 IN-3 suppresses tumor growth. This compound is applicable for research in multiple myeloma.

UP12 enhances ATPase activity by activating valosin-containing protein (VCP), with an EC50 of 2.57 μM.

p97-IN-1 is an orally active inhibitor of p97 with an IC50 of 26 nM. It significantly impedes the proliferation of tumor cells and is applicable for research in acute myeloid leukemia (AML).

VCP/p97 IN-2 (Compound V13) is a VCP/p97 inhibitor with an IC50 of 32 nM for p97. It exhibits excellent antitumor activity, significantly suppressing tumor growth in a Molm-13 xenograft mouse model. VCP/p97 IN-2 is applicable for research in acute myeloid leukemia (AML).

NW 1028 is a potent inhibitor of VCP/p97. NW 1028 selectively acts on the ND1L domain of p97 and inhibits the degradation of p97-dependent reporter genes. NW 1028 has a regulatory effect on the mitotic spindle.

ML241 is a potent and selective inhibitors of p97 ATPase.

UPCDC30766, a potent allosteric inhibitor of p97, exhibits an IC50 of 12 nM and is applicable for colon cancer research [1].

VCP/p97 inhibitor-1, a highly effective compound, inhibits VCP/p97 (also known as Cdc48, CDC-48, or Ter94) with an IC 50 of 54.7 nM. This inhibitor induces a disruption in protein homeostasis and interferes with the degradation process of misfolded polypeptides by the ubiquitin-proteasome system (UPS).